# SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers

> **NCT02797236** · PHASE1 · COMPLETED · sponsor: **Institut Pasteur** · enrollment: 64 (actual)

## Conditions studied

- Shigellosis
- Bacillary Dysentery

## Interventions

- **BIOLOGICAL:** SF2a-TT15 vaccine
- **BIOLOGICAL:** SF2a-TT15 vaccine + adjuvant
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Placebo + adjuvant

## Key facts

- **NCT ID:** NCT02797236
- **Lead sponsor:** Institut Pasteur
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-06
- **Final completion:** 2017-12
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2018-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02797236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02797236, "SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02797236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*